Adverse events ( AEs ) were similar between the two enzalutamide age groups , with the exception of an increase in patients75 years in the rates of all grade peripheral edema ( 22.1 % versus 12.5 % ) , fatigue ( 39.7 % versus 31.6 % ) , and diarrhea ( 26.6 % versus 19.6 % ) .